<DOC>
	<DOCNO>NCT02610413</DOCNO>
	<brief_summary>This research trial study whole exome sequence find causative variant germline deoxyribonucleic acid ( DNA ) sample patient hypertension receive bevacizumab breast cancer . Studying sample germline DNA laboratory patient hypertension receive bevacizumab breast cancer may help doctor learn change occur DNA identify biomarkers related hypertension .</brief_summary>
	<brief_title>Whole Exome Sequencing Finding Causative Variants Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To identify , use next generation sequencing , rare variant large effect size impact risk hypertension patient clinical trial Eastern Cooperative Oncology Group ( ECOG ) -5103 ( E5103 ) . OUTLINE : Previously collect germline DNA sample analyze via whole exome sequencing .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>European American patient deoxyribonucleic acid ( DNA ) available designated case control Patients develop grade 34 bevacizumabinduced hypertension treatment bevacizumab Patients develop hypertension follow full course treatment bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>